Evaluation of efficacy of moxifloxacin (0.5%) in the treatment of non-perforated bacterial corneal ulcers

Evaluation of efficacy of moxifloxacin (0.5%) in the treatment of non-perforated bacterial corneal ulcers: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10323655

Enrollment

150

Registered

2010-08-11

Start date

2009-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal ulcer Eye Diseases Keratitis

Interventions

Drug instillation protocol: 1. First 48 hours: 1 drop hourly, day and night 2. Day 3: 1 drop hourly by daya and every 2 hours at night 3. Days 4 - 5: 1 drop every 2 hours by day and every 4 hours by

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-perforated bacterial corneal ulcers

Exclusion criteria

Exclusion criteria: 1. Known allergy to fluoroquinolones, aminoglycosides, penicillins,cephalosporins or benzalkoniun chloride 2. Patients with fungal, viral or acanthamoeba infection 3. Patients to be treated with subconjuctival injection(s) of antibiotic(s) and/or with systemic antimicrobials 4. Patients aged 16 - 65 years 5. Pregnant and lactating females 6. Any adverse effects or protocol violations 7. Perforated corneal ulcers

Design outcomes

Primary

Measure	Time frame
1. Time to epithelialisation 2. Time to resolution of the infiltrates All outcomes were measured on days 2, 4, 7, 14, 21 and at 3 months.	—

Secondary

Measure	Time frame
1. Uncorrected Visual Acuity (UCVA) 2. Best Corrected Visual Acuity (BCVA) All outcomes were measured on days 2, 4, 7, 14, 21 and at 3 months.	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026